 For ethical reasons to give opportunity for adult subjects 16 or 18 years suffering from newly diagnosed epilepsy who completed the therapeutic confirmatory, open-label trial N01175 NCT00175903 conducted with levetiracetam in monotherapy and who benefited from the treatment, to receive treatment with levetiracetam until the monotherapy indication for levetiracetam is granted in Europe. 